Connect Sign In
FeedbackFlow Cytometry
- Use to detect MRD in patients of all ages previously diagnosed with B-ALL.
- Available antigen markers include CD3, CD9, CD10, CD13, CD19, CD20, CD22, CD24, CD33, CD34, CD38, CD45, CD58, CD66b, CD71, and Syto 16.
- Anti-CD19 resistant markers (CD10, CD19, CD20, CD22, CD24, CD34, CD38, CD45, CD58, CD66b) will be used for bone marrow testing unless a Children’s Oncology Group (COG) protocol is specified and there is no prior history of COG bone marrow testing.
- Orders for whole blood testing will be canceled if the patient is 18 years or older or if there is a prior history of COG whole blood testing.
B-cell acute lymphoblastic leukemia (B-ALL) is an aggressive leukemia of B-cell lineage involving immature lymphoid cells. It is primarily a childhood disease. B-ALL minimal residual disease (MRD) testing by flow cytometry may be useful for prognosis and monitoring of the disease and for the detection of MRD but should not be used for initial diagnosis; instead, a comprehensive flow cytometry panel is recommended. For information on initial diagnostic testing, refer to the Leukemia/Lymphoma Phenotyping Evaluation by Flow Cytometry Test Fact Sheet. For more information about the overall testing strategy for B-ALL, refer to the ARUP Consult Acute Lymphoblastic Leukemia - ALL topic.
Test Description
This test is useful for the evaluation of MRD, specifically B-ALL blasts. Leukocytes are evaluated for the presence of immature/blast cells.
Antigen Markers Used and Reported
The reported markers vary based on the specimen submitted and whether the Children’s Oncology Group (COG) protocol is specified at the time of ordering. The COG protocol is typically not specified unless the patient is on a COG protocol. If the COG protocol is specified, the time point and specimen type must be indicated.
A 10-color panel that is resistant to anti-CD19 therapy (including monoclonal antibodies or chimeric antigen receptor T-cell therapy [CAR-T]) is used; this panel offers superior sensitivity in most clinical scenarios.
| Protocol Specified | Specimen Type Submitted | Antigen Markers Used and Reported |
|---|---|---|
| None | Bone marrow | CD10, CD19, CD20, CD22, CD24, CD34, CD38, CD45, CD58, CD66b |
| COG | Bone marrow with prior history of COG bone marrow | CD10, CD19, CD20, CD22, CD24, CD34, CD38, CD45, CD58, CD66b |
| COG | Day 29 bone marrow without prior history of COG bone marrow | CD3, CD9, CD10, CD13, CD19, CD20, CD33, CD34, CD38, CD45, CD58, CD71, Syto 16 |
| None | Whole blood | None; testing will be canceled |
| COG | Whole blood with prior history of COG whole blood testing | None; testing will be canceled |
| COG | Day 8 whole blood without prior history of COG whole blood testing | If patient is <18 years of age: CD10, CD19, CD20, CD34, CD45, Syto 16 If patient is ≥18 years of age: none; testing will be canceled |
Test Interpretation
Sensitivity/Specificity
Analytic Specificity
Discrimination by forward scatter, side scatter, CD45 intensity, and specific antigen markers
Analytic Sensitivity (Limit of Detection)
Anti-CD19 resistant panel (non-COG panel): 0.0072% of viable leukocytes
COG panel: 0.01% of nucleated mononuclear cells
- This panel has poor sensitivity in patients treated with anti-CD19 therapy.
Results
- Antigen markers will be reported as positive or negative.
- Positive results will be reported as a percentage of viable leukocytes or nucleated mononuclear cells.
- Pathologist interpretation of findings is included.
Limitations
- The COG panel has poor sensitivity in patients treated with an anti-CD19 therapy; consider the non-COG panel.
- Poor cell viability may adversely affect antigens and impede the ability to properly identify neoplastic cells.
- Hemodilution or low numbers of events collected may affect sensitivity.
- First-pull aspirate is recommended for maximum sensitivity.
- Flow results should not be used alone to diagnose malignancy.
- Results should be interpreted in conjunction with morphology, clinical information, and other necessary ancillary tests for a definitive diagnosis.
References
-
NCCN - pediatric acute lymphoblastic leukemia v3.2024
National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: pediatric acute lymphoblastic leukemia. Version 3.2024. Updated Oct 2023; accessed Nov 2023.